Patent SG-11201903091V-A (SG)
Title: Quinoxaline compounds as type iii receptor tyrosine kinase inhibitors
Inventor: PENG SHAO-ZHENG
IPC: C07D401/12
Filed: 2017-10-09
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property MD 1101111 0 DOI HIM 011101 0 011111111 011100111111110111110111101111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2018/071348 Al 19 April 2018 (19.04.2018) WIP0 1 PCT (51) International Patent Classification: UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, C07D 241/40 (2006.01) C07D 401/12 (2006.01) TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, C07D 241/44 (2006.01) EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (21) International Application Number: MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, PCT/US2017/055809 TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (22) International Filing Date: 09 October 2017 (09.10.2017) Published: (25) Filing Language: — English with international search report (Art. 21(3)) (26) Publication Language: English (30) Priority Data: 62/406,328 10 October 2016 (10.10.2016) US (71) Applicants: DEVELOPMENT CENTER FOR BIOTECHNOLOGY; No. 101, Lane 169, Kangning St , New Taipei City, 221 (TW). DCB-USA LLC [US/US]; 1007 N. Orange Street, Wilmington, DE 19801 (US). (72) Inventors: PENG, Shao-Zheng; c/o DCB, No. 101, Lane _ 169, Kangning St., New Taipei City, 221 (TW). LIAO, _ Chu-bin; c/o DCB, No. 101, Lane 169, Kangning St New , Taipei City, 221 (TW). CHEN, Hung-Kai; c/o DCB, No. = 101, Lane 169, Kangning St., New Taipei City, 221 (TW). HO, Chen-Hsuan; c/o DCB, No. 101, Lane 169, Kangning = St., New Taipei City, 221 (TW). HUANG, Hung-Jyun; c/ o DCB, No. 101, Lane 169, Kangning St., New Taipei City, 221 (TW). CHIOU, Shian-Yi; c/o DCB, No. 101, Lane — = 169, Kangning St., New Taipei City, 221 (TW). (74) Agent: LIANG, T., Chyau; Liang Legal Group, PLLC, 6020 Annapolis Street, Houston, TX 77005 (US). — — Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, = (81) = = CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, — DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, = HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, = = OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, = — SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, = TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every = kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, — 1-1 GC (54) Title: QUINOXALINE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS 71' M (57) : A compound, capable of inhibiting kinases, for the treat- 1-1 R 2 ments of diseases or disorders mediated by such kinases, has a structure IN R 1 X R14] of formula (I) or a stereoisomer, a tautomer, a pharmaceutically accept- = --.... (I) able salt thereof. The compound can be used in the treatments of diseases 1 0 1-1 N U Z G or conditions mediated by CSF-IR, c-KIT, FLT3, or PDGFR kinases. = ei Such diseases or conditions may include cancers, autoimmune diseases, and bone resorptive diseases. O